Patents Assigned to Obio Pharmaceutical (H.K.) Limited
  • Patent number: 9283198
    Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: March 15, 2016
    Assignee: OBIO PHARMACEUTICAL (H.K.) LIMITED
    Inventors: Hao Yi Liang, Francis Chi, Qingfu Xu, Bill Piu Chan
  • Publication number: 20140011887
    Abstract: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.
    Type: Application
    Filed: September 9, 2013
    Publication date: January 9, 2014
    Applicant: OBIO PHARMACEUTICAL (H.K.) LIMITED
    Inventors: WEN QIN TANG, FRANCIS CHI
  • Publication number: 20130338113
    Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).
    Type: Application
    Filed: April 4, 2013
    Publication date: December 19, 2013
    Applicant: OBIO PHARMACEUTICAL (H.K.) LIMITED
    Inventors: HAO YI LIANG, FRANCIS CHI, QINGFU XU, BILL PIU CHAN
  • Patent number: 8415398
    Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: April 9, 2013
    Assignee: Obio Pharmaceutical (H.K.) Limited
    Inventors: Hao Yi Liang, Francis Chi, Qingfu Xu, Bill Piu Chan